DK2968269T3 - Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter - Google Patents

Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter Download PDF

Info

Publication number
DK2968269T3
DK2968269T3 DK14768236.3T DK14768236T DK2968269T3 DK 2968269 T3 DK2968269 T3 DK 2968269T3 DK 14768236 T DK14768236 T DK 14768236T DK 2968269 T3 DK2968269 T3 DK 2968269T3
Authority
DK
Denmark
Prior art keywords
agonists
intermediates
procedure
preparing beta
beta
Prior art date
Application number
DK14768236.3T
Other languages
English (en)
Inventor
Feng Xu
Zhuqing Liu
Richard Desmond
Jeonghan Park
Alexei Kalinin
Birgit Kosjek
Hallena Strotman
Hongmei Li
Johannah Moncecchi
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2968269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2968269T3 publication Critical patent/DK2968269T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK14768236.3T 2013-03-15 2014-03-12 Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter DK2968269T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791247P 2013-03-15 2013-03-15
PCT/US2014/023858 WO2014150639A1 (en) 2013-03-15 2014-03-12 Process for preparing beta 3 agonists and intermediates

Publications (1)

Publication Number Publication Date
DK2968269T3 true DK2968269T3 (da) 2019-10-07

Family

ID=51580798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14768236.3T DK2968269T3 (da) 2013-03-15 2014-03-12 Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter

Country Status (16)

Country Link
US (7) US10287289B2 (da)
EP (2) EP2968269B1 (da)
JP (1) JP6383403B2 (da)
CY (1) CY1122690T1 (da)
DK (1) DK2968269T3 (da)
ES (1) ES2746801T3 (da)
HR (1) HRP20191546T1 (da)
HU (1) HUE045260T2 (da)
LT (1) LT2968269T (da)
ME (1) ME03506B (da)
PL (1) PL2968269T3 (da)
PT (1) PT2968269T (da)
RS (1) RS59402B1 (da)
SI (1) SI2968269T1 (da)
SM (1) SMT201900508T1 (da)
WO (1) WO2014150639A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法
CN104496875B (zh) * 2014-12-12 2017-09-08 常州大学 2‑烯丙基‑2‑甲醛基‑n‑苯基吡咯碄的合成方法
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
SG11202010683PA (en) 2018-05-23 2020-12-30 Urovant Sciences Gmbh Use of vibegron to treat pain associated with irritable bowel syndrome
TW202038963A (zh) 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆(vibegron)於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途
TW202506129A (zh) 2019-03-18 2025-02-16 瑞士商優洛凡特科學公司 維貝隆(vibegron)用於治療膀胱過動症之用途
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
AR124479A1 (es) 2020-12-22 2023-03-29 Urovant Sciences Gmbh Métodos de monitoreo de la digoxina con el uso de vibegrón para el tratamiento de la vejiga hiperactiva
TW202245781A (zh) 2021-02-16 2022-12-01 瑞士商優洛凡特科學公司 用維貝格龍(vibegron)治療心臟衰竭之方法
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法
CN117467628B (zh) * 2023-09-18 2024-04-16 长兴制药股份有限公司 一种酮还原酶及其制备高光学纯度β-3肾上腺素能激动剂中间体的方法
WO2025262600A1 (en) 2024-06-17 2025-12-26 Urovant Sciences Gmbh Crystalline form of vibegron hemihydrate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) 2002-02-27 2003-08-30 Pfizer Prod Inc AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
KR101586503B1 (ko) 2007-09-13 2016-01-18 코덱시스, 인코포레이티드 아세토페논의 환원을 위한 케토리덕타제 폴리펩티드
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
SI2329014T1 (sl) * 2008-08-29 2015-01-30 Codexis, Inc. Polipeptidi ketoreduktaze za stereoselektivno produkcijo (4s)-3(5s)-5(4-fluorofenil)-5-hidroksipentanoil)-4-fenil-1,3-oksazolidin -2-ona
US20120202819A1 (en) 2009-10-07 2012-08-09 Merck Sharp & Dohme Corporation Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent
CA2796877A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
CN106479990B (zh) * 2011-11-18 2020-09-18 科德克希思公司 用于制备羟基取代的氨基甲酸酯的生物催化剂
JP6383403B2 (ja) 2013-03-15 2018-08-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. β−3作動薬および中間体の製造方法

Also Published As

Publication number Publication date
SMT201900508T1 (it) 2019-11-13
US10696681B2 (en) 2020-06-30
JP6383403B2 (ja) 2018-08-29
WO2014150639A1 (en) 2014-09-25
RS59402B1 (sr) 2019-11-29
JP2016515117A (ja) 2016-05-26
US11091493B2 (en) 2021-08-17
US20250304588A1 (en) 2025-10-02
EP2968269B1 (en) 2019-07-10
HUE045260T2 (hu) 2019-12-30
US20170145014A1 (en) 2017-05-25
ES2746801T3 (es) 2020-03-06
CY1122690T1 (el) 2021-03-12
ME03506B (me) 2020-04-20
LT2968269T (lt) 2019-10-25
EP3597737A1 (en) 2020-01-22
PT2968269T (pt) 2019-10-08
US20240300955A1 (en) 2024-09-12
PL2968269T3 (pl) 2020-03-31
EP2968269A4 (en) 2016-12-28
US20240300960A1 (en) 2024-09-12
US20190194211A1 (en) 2019-06-27
US12180219B2 (en) 2024-12-31
US20200392141A1 (en) 2020-12-17
US11649243B2 (en) 2023-05-16
EP2968269A1 (en) 2016-01-20
HRP20191546T1 (hr) 2019-11-29
US10287289B2 (en) 2019-05-14
US20220073523A1 (en) 2022-03-10
SI2968269T1 (sl) 2019-12-31

Similar Documents

Publication Publication Date Title
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3006568T3 (da) Fremgangsmåde til fremstilling af tagatose
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3368060T3 (da) Glugacon-receptor-agonister
DK3545906T3 (da) Indretning til udskiftning af hjerteklap
DK3300610T3 (da) Fremgangsmåde til fraktionering af opløselige ærter
DK2996556T3 (da) System til billedstyret procedure
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3556869T3 (da) Sammensætninger og fremgangsmåder til sekventering af polynukleotider
DK3294700T3 (da) Fremgangsmåde til fremstilling af limonen-4-ol
DK3027186T3 (da) Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid
DK3219707T3 (da) Fremgangsmåde til fremstilling af substituerede oxiraner og triazoler
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
PL2968269T3 (pl) Sposób przygotowywania agonistów beta-3 i produktów pośrednich
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK2811761T3 (da) Antenneindretning til høreinstrumenter
DK2992104T3 (da) Fremgangsmåde til ekspression
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2979399T3 (da) Fremgangsmåde og anordning til justering af latenstid
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3080302T3 (da) Metoder og sonder til identifikation af genalleler
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
DK3369724T3 (da) Fremgangsmåde til fremstilling af iopamidol
HUE049425T2 (hu) GPR120 agonista biaril-származékok
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose